Dr Yelena Yuriy Janjigian speaks to ecancer about circulating tumour DNA status to direct adjuvant immunotherapy for mismatch repair-deficient tumours.

The study explores how circulating tumour DNA (ctDNA) can guide adjuvant immunotherapy for mismatch repair-deficient tumours.

It highlights ctDNA as a real-time biomarker for minimal residual disease, predicting cancer recurrence risk.

The research shows that ctDNA detection post-surgery can identify patients needing immunotherapy.

Results indicate high recurrence-free survival for ctDNA negative patients, while ctDNA positive patients face lower rates, emphasising the need for further interventions.